SCHEDULE: Soleus Entities Update Passive Stake in Immunic, Inc.

Soleus Private Equity Fund III, L.P., Soleus Capital Master Fund, L.P., and related entities, including Guy Levy, updated their passive beneficial ownership in Immunic, Inc., collectively holding 1.6% of common stock.

Summary

• Soleus Private Equity Fund III, L.P. and its related general partner entities (Soleus Private Equity GP III, LLC and Soleus PE GP III, LLC) beneficially own 1,060,457 shares of Immunic, Inc. common stock, representing 1.1% of the class.
• Soleus Capital Master Fund, L.P. and its related general partner entities (Soleus Capital, LLC and Soleus Capital Group, LLC) beneficially own 519,550 shares of Immunic, Inc. common stock, representing 0.5% of the class.
• Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy (as the sole managing member of key entities) collectively beneficially own 1,580,007 shares of Immunic, Inc. common stock, representing 1.6% of the class.
• The percentage of class is calculated based on 98,650,590 shares of Immunic, Inc. common stock outstanding as of July 31, 2025, as reported in the Issuer's Form 10-Q filed on August 7, 2025.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Immunic, Inc.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership and does not contain information that would significantly alter the company's perceived value or outlook. It is a passive investment update.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership structure and the extent of passive investment by Soleus entities and Guy Levy.

Key Dates

Keywords

Immunic, Soleus, beneficial ownership, Schedule 13G, common stock, institutional investment, passive investment